The development of a patient-reported outcome measure for assessing nighttime symptoms of chronic obstructive pulmonary disease

Health and Quality of Life Outcomes

Volumn 11, Issue 1, 2013, Pages

  Hareendran, Asha ^a   Palsgrove, Andrew C ^a   Mocarski, Michelle ^b   Schaefer, Michael L ^a   Setyawan, Juliana ^b   Carson, Robyn ^b   Make, Barry ^c  

^a UNITED BIOSOURCE CORPORATION   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

^c DEPARTMENT OF MEDICINE   (United States)

Author keywords

Awakening; COPD; Nighttime; PRO; Symptoms

Indexed keywords

AGED; AROUSAL; ARTICLE; CHEST TIGHTNESS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONCEPTUAL FRAMEWORK; CONTENT VALIDITY; COUGHING; DISEASE SEVERITY; DYSPNEA; FEMALE; FOLLOW UP; HEADACHE; HOSPITAL ANXIETY AND DEPRESSION SCALE; HUMAN; INTERVIEW; MALE; OUTCOME ASSESSMENT; SNORING; SYMPTOM; WHEEZING;

AGED; FEMALE; FOCUS GROUPS; HEALTH STATUS INDICATORS; HUMANS; INTERVIEWS AS TOPIC; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PSYCHOMETRICS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUESTIONNAIRES; REPRODUCIBILITY OF RESULTS; SELF REPORT;

EID: 84879222847     PISSN: None     EISSN: 14777525     Source Type: Journal    
DOI: 10.1186/1477-7525-11-104     Document Type: Article

References (22)

1. Vestbo J, Hurd SS, Agusti AG, Jones PW, Vogelmeier C, Anzueto A, Barnes PJ, Fabbri LM, Martinez FJ, Nishimura M, et al. Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Pulmonary Disease, GOLD Executive Summary. Am J Respir Crit Care Med 2013, 187:347-365. 10.1164/rccm.201204-0596PP, 22878278.
2. Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J. Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002, 20:799-805. 10.1183/09031936.02.03242002, 12412667.
3. Agusti A, Hedner J, Marin JM, Barbe F, Cazzola M, Rennard S. Night-time symptoms: a forgotten dimension of COPD. Eur Respir Rev 2011, 20:183-194. 10.1183/09059180.00004311, 21881146.
4. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009, 25:2043-2048. 10.1185/03007990903103006, 19569976.
5. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, et al. Outcomes for COPD pharmacological trials: from lung function to biomarkers. Eur Respir J 2008, 31:416-469. 10.1183/09031936.00099306, 18238951.
6. Magnussen H, Verkindre C, Jack D, Jadayel D, Henley M, Woessner R, Higgins M, Kramer B. Indacaterol once-daily is equally effective dosed in the evening or morning in COPD. Respir Med 2010, 104:1869-1876. 10.1016/j.rmed.2010.08.010, 20850959.
7. Lofdahl C. Reducing the impact of COPD exacerbations: Clinical efficacy of budesonide/formoterol. Eur Respir Rev 2004, 13:14-21.
8. Make B, Hanania NA, ZuWallack R, Kalberg C, Emmett A, Brown CP, Knobil K. The efficacy and safety of inhaled fluticasone propionate/salmeterol and ipratropium/albuterol for the treatment of chronic obstructive pulmonary disease: an eight-week, multicenter, randomized, double-blind, double-dummy, parallel-group study. Clin Ther 2005, 27:531-542. 10.1016/j.clinthera.2005.05.009, 15978302.
9. Zheng JP, Yang L, Wu YM, Chen P, Wen ZG, Huang WJ, Shi Y, Wang CZ, Huang SG, Sun TY, et al. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD. Chest 2007, 132:1756-1763. 10.1378/chest.06-3009, 17951625.
10. Kerwin EM, D'Urzo AD, Gelb AF, Lakkis H, Garcia Gil E, Caracta CF. Efficacy and safety of a 12-week treatment with twice-daily aclidinium bromide in COPD patients (ACCORD COPD I). COPD 2012, 9:90-101. 10.3109/15412555.2012.661492, 22320148.
11. Terzano C, Petroianni A, Conti V, Ceccarelli D, Graziani E, Sanduzzi A, D'Avelli S. Rational timing of combination therapy with tiotropium and formoterol in moderate and severe COPD. Respir Med 2008, 102:1701-1707. 10.1016/j.rmed.2008.07.012, 18760583.
12. United States Food and Drug Administration Guidance for industry on patient-reported outcome measures: use in medical product development to support labeling claims. Fed Regist 2009, 74:65132-65133. United States Food and Drug Administration.
13. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO good research practices task force report: part 1-eliciting concepts for a new PRO instrument. Value Health 2011, 14:967-977. 10.1016/j.jval.2011.06.014, 22152165.
14. Patrick DL, Burke LB, Gwaltney CJ, Leidy NK, Martin ML, Molsen E, Ring L. Content validity-establishing and reporting the evidence in newly developed patient-reported outcomes (PRO) instruments for medical product evaluation: ISPOR PRO Good Research Practices Task Force report: part 2-assessing respondent understanding. Value Health 2011, 14:978-988. 10.1016/j.jval.2011.06.013, 22152166.
15. Meguro M, Barley EA, Spencer S, Jones PW. Development and validation of an improved, COPD-specific version of the St. George Respiratory Questionnaire. Chest 2007, 132:456-463. 10.1378/chest.06-0702, 17646240.
16. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145:1321-1327. 10.1164/ajrccm/145.6.1321, 1595997.
17. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983, 67:361-370. 10.1111/j.1600-0447.1983.tb09716.x, 6880820.
18. Snaith RP. The Hospital Anxiety And Depression Scale. Health Qual Life Outcomes 2003, 1:29. 10.1186/1477-7525-1-29, 183845, 12914662.
19. Polit DF, Hungler BP. Nursing research: principles and methods 1995, Philadelphia: Lippincott Williams and Wilkins, 6.
20. Pope C, Ziebland S, Mays N. Qualitative research in health care. Analysing qualitative data. BMJ 2000, 320:114-116. 10.1136/bmj.320.7227.114, 1117368, 10625273.
21. Muhr T. User's Manual for ATLAS.ti 5.0 2004, Berlin: ATLAS.ti Scientific Software Development GmbH.
22. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, Calverley P, Fukuchi Y, Jenkins C, Rodriguez-Roisin R, van Weel C, Zielinski J. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007, 176:532-555. 10.1164/rccm.200703-456SO, 17507545.